Startseite › Kolorektales Karzinom › Pennsylvania › Pittsburgh
Klinische Studien zu Kolorektales Karzinom in Pittsburgh, PA
32 Studien zu Kolorektales Karzinom suchen Teilnehmer an Standorten in und um Pittsburgh (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Teilnehmer gesuchtPhase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
Teilnehmer gesuchtPhase 2
- Allegheny General Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Teilnehmer gesuchtPhase 1
- Exelixis Clinical Site #32, Pittsburgh
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Teilnehmer gesuchtPhase 1
- Research Site, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Teilnehmer gesuchtPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Teilnehmer gesuchtPhase 1/2
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Teilnehmer gesuchtPhase 3
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1
- Research Site, Pittsburgh
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Teilnehmer gesuchtPhase 3
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Teilnehmer gesuchtPhase 3
- Allegheny General Hospital, Pittsburgh
- West Penn Hospital, Pittsburgh
- Jefferson Hospital, Jefferson Hills · 11 mi entfernt
- und 2 weitere
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Teilnehmer gesuchtPhase 2/3
- Local Institution - 0604, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Teilnehmer gesuchtPhase 1
- University of Pittsburgh Medical Center, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Allegheny Health Network, Pittsburgh
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Teilnehmer gesuchtPhase 3
- Allegheny General Hospital Cancer Institute, Pittsburgh
- Hillman Cancer Center, Pittsburgh
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Teilnehmer gesuchtPhase 3
- Clinical Study Site, Pittsburgh
- Clinical Study Site, Pittsburgh
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Teilnehmer gesuchtPhase 2
- UPMC / University of Pittsburgh Medical Center, Pittsburgh
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Teilnehmer gesuchtPhase 1/2
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Teilnehmer gesuchtPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
Teilnehmer gesuchtPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Teilnehmer gesuchtPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Teilnehmer gesuchtPhase 3
- UPMC Hillman Cancer Center - St Margarets, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC Hillman Cancer Center - Passavant (HOA), Pittsburgh
- und 6 weitere
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Teilnehmer gesuchtPhase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar
Teilnehmer gesucht
- Allegheny Health Network, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Teilnehmer gesuchtPhase 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
Teilnehmer gesuchtPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
Teilnehmer gesucht
- AHN West Penn Hospital, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Kolorektales Karzinom-Studien in anderen Städten
- Houston, TX102 Studien
- New York City, NY78 Studien
- Nashville, TN69 Studien
- Boston, MA63 Studien
- Los Angeles, CA59 Studien
- Arlington, VA52 Studien
- St. Louis, MO50 Studien
- San Antonio, TX46 Studien
- Philadelphia, PA44 Studien
- Grand Rapids, MI40 Studien
- Baldwin Park, CA37 Studien
- Chicago, IL34 Studien
Weitere Studien in Pittsburgh
- Nichtkleinzelliges Lungenkarzinom48 Studien
- Krebs (alle Arten)41 Studien
- Brustkrebs39 Studien
- Metastasierender Krebs31 Studien
- Melanom31 Studien
- Eierstockkrebs30 Studien
- Endometriumkarzinom23 Studien
- Prostatakrebs23 Studien
- Lungenkrebs23 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich22 Studien
- Schlaganfall22 Studien
- Depression22 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.